Details for New Drug Application (NDA): 020638
✉ Email this page to a colleague
The generic ingredient in VISTIDE is cidofovir. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the cidofovir profile page.
Summary for 020638
Tradename: | VISTIDE |
Applicant: | Gilead Sciences Inc |
Ingredient: | cidofovir |
Patents: | 0 |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 75MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Jun 26, 1996 | TE: | RLD: | Yes |
Expired US Patents for NDA 020638
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Gilead Sciences Inc | VISTIDE | cidofovir | INJECTABLE;INJECTION | 020638-001 | Jun 26, 1996 | 5,142,051 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription